Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer. Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcome...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-01, Vol.16 (2), p.4409-4418 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4418 |
|---|---|
| container_issue | 2 |
| container_start_page | 4409 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Rizzo, Alessandro Mollica, Veronica Ricci, Angela Dalia Maggio, Ilaria Massucci, Maria Rojas Limpe, Fabiola Lorena Fabio, Francesca Di Ardizzoni, Andrea |
| description | We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer.
Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcomes of interest included: overall survival, objective response rate and disease control rate in TLT; progression-free survival in ST; grade 3–4 adverse events in ST.
The use of TLT and ST was superior to placebo or best supportive care in terms of prolonging overall survival and progression-free survival. Hematological toxicities were more frequent in ST.
TLT and ST are considerable and tolerable treatment options for patients with advanced or metastatic gastric cancer. Given the substantial heterogeneities affecting the efficacy analyses, these results have to be interpreted cautiously. |
| doi_str_mv | 10.2217/fon-2019-0429 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2320887873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473389951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-99cd0c3453ac968667dc97d59161cc7154f0a35942b326aa2a4e7a7c66bd0f313</originalsourceid><addsrcrecordid>eNp1kTtvFTEQhS0EIi9KWmSJhsbEr7XXdCgCghQpTVJbc-1ZcLSPYHsT3X-PNzdQIFHNjOabo9E5hLwV_KOUwp4Py8wkF45xLd0Lciys1qxXXLxsvbaOGeP0ETkp5Y5zbVXHX5MjJaxTSstjstz8TDkyCnOkI1TMbEwz0poR6oRzpWmmEB9gDhjpkumEFUqFmgL90ZrcatiW-RMFWval4vS0zPiQ8PFJdjthMMO4L6mckVcDjAXfPNdTcvv1y83FJbu6_vb94vMVC1rZypwLkQelOwXBmd4YG4OzsXPCiBCs6PTAQXVOy52SBkCCRgs2GLOLfFBCnZIPB937vPxasVQ_pRJwHGHGZS1eKsn73vZWNfT9P-jdsub2b6OaYap3rtsE2YEKeSkl4-Dvc5og773gfkvCtyT8loTfkmj8u2fVdTdh_Ev_sb4B7gAMa10zlpCw-egPU7tIoQXxH_Hf9JSXpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473389951</pqid></control><display><type>article</type><title>Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Rizzo, Alessandro ; Mollica, Veronica ; Ricci, Angela Dalia ; Maggio, Ilaria ; Massucci, Maria ; Rojas Limpe, Fabiola Lorena ; Fabio, Francesca Di ; Ardizzoni, Andrea</creator><creatorcontrib>Rizzo, Alessandro ; Mollica, Veronica ; Ricci, Angela Dalia ; Maggio, Ilaria ; Massucci, Maria ; Rojas Limpe, Fabiola Lorena ; Fabio, Francesca Di ; Ardizzoni, Andrea</creatorcontrib><description>We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer.
Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcomes of interest included: overall survival, objective response rate and disease control rate in TLT; progression-free survival in ST; grade 3–4 adverse events in ST.
The use of TLT and ST was superior to placebo or best supportive care in terms of prolonging overall survival and progression-free survival. Hematological toxicities were more frequent in ST.
TLT and ST are considerable and tolerable treatment options for patients with advanced or metastatic gastric cancer. Given the substantial heterogeneities affecting the efficacy analyses, these results have to be interpreted cautiously.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2019-0429</identifier><identifier>PMID: 31793342</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; biological therapy ; Cancer therapies ; chemotherapy ; Clinical trials ; Clinical Trials, Phase III as Topic ; Gastric cancer ; Gastroenterology ; gastrointestinal/colorectal ; Humans ; Medical prognosis ; Meta-analysis ; Metastasis ; molecular oncology ; Neoplasm Metastasis ; Oncology ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Salvage Therapy - methods ; solid tumors ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Survival Rate ; Systematic review</subject><ispartof>Future oncology (London, England), 2020-01, Vol.16 (2), p.4409-4418</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jan 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-99cd0c3453ac968667dc97d59161cc7154f0a35942b326aa2a4e7a7c66bd0f313</citedby><cites>FETCH-LOGICAL-c437t-99cd0c3453ac968667dc97d59161cc7154f0a35942b326aa2a4e7a7c66bd0f313</cites><orcidid>0000-0002-5257-8678</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31793342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rizzo, Alessandro</creatorcontrib><creatorcontrib>Mollica, Veronica</creatorcontrib><creatorcontrib>Ricci, Angela Dalia</creatorcontrib><creatorcontrib>Maggio, Ilaria</creatorcontrib><creatorcontrib>Massucci, Maria</creatorcontrib><creatorcontrib>Rojas Limpe, Fabiola Lorena</creatorcontrib><creatorcontrib>Fabio, Francesca Di</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><title>Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer.
Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcomes of interest included: overall survival, objective response rate and disease control rate in TLT; progression-free survival in ST; grade 3–4 adverse events in ST.
The use of TLT and ST was superior to placebo or best supportive care in terms of prolonging overall survival and progression-free survival. Hematological toxicities were more frequent in ST.
TLT and ST are considerable and tolerable treatment options for patients with advanced or metastatic gastric cancer. Given the substantial heterogeneities affecting the efficacy analyses, these results have to be interpreted cautiously.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>biological therapy</subject><subject>Cancer therapies</subject><subject>chemotherapy</subject><subject>Clinical trials</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Gastric cancer</subject><subject>Gastroenterology</subject><subject>gastrointestinal/colorectal</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metastasis</subject><subject>molecular oncology</subject><subject>Neoplasm Metastasis</subject><subject>Oncology</subject><subject>Progression-Free Survival</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Salvage Therapy - methods</subject><subject>solid tumors</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Rate</subject><subject>Systematic review</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kTtvFTEQhS0EIi9KWmSJhsbEr7XXdCgCghQpTVJbc-1ZcLSPYHsT3X-PNzdQIFHNjOabo9E5hLwV_KOUwp4Py8wkF45xLd0Lciys1qxXXLxsvbaOGeP0ETkp5Y5zbVXHX5MjJaxTSstjstz8TDkyCnOkI1TMbEwz0poR6oRzpWmmEB9gDhjpkumEFUqFmgL90ZrcatiW-RMFWval4vS0zPiQ8PFJdjthMMO4L6mckVcDjAXfPNdTcvv1y83FJbu6_vb94vMVC1rZypwLkQelOwXBmd4YG4OzsXPCiBCs6PTAQXVOy52SBkCCRgs2GLOLfFBCnZIPB937vPxasVQ_pRJwHGHGZS1eKsn73vZWNfT9P-jdsub2b6OaYap3rtsE2YEKeSkl4-Dvc5og773gfkvCtyT8loTfkmj8u2fVdTdh_Ev_sb4B7gAMa10zlpCw-egPU7tIoQXxH_Hf9JSXpg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Rizzo, Alessandro</creator><creator>Mollica, Veronica</creator><creator>Ricci, Angela Dalia</creator><creator>Maggio, Ilaria</creator><creator>Massucci, Maria</creator><creator>Rojas Limpe, Fabiola Lorena</creator><creator>Fabio, Francesca Di</creator><creator>Ardizzoni, Andrea</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5257-8678</orcidid></search><sort><creationdate>20200101</creationdate><title>Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis</title><author>Rizzo, Alessandro ; Mollica, Veronica ; Ricci, Angela Dalia ; Maggio, Ilaria ; Massucci, Maria ; Rojas Limpe, Fabiola Lorena ; Fabio, Francesca Di ; Ardizzoni, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-99cd0c3453ac968667dc97d59161cc7154f0a35942b326aa2a4e7a7c66bd0f313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>biological therapy</topic><topic>Cancer therapies</topic><topic>chemotherapy</topic><topic>Clinical trials</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Gastric cancer</topic><topic>Gastroenterology</topic><topic>gastrointestinal/colorectal</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metastasis</topic><topic>molecular oncology</topic><topic>Neoplasm Metastasis</topic><topic>Oncology</topic><topic>Progression-Free Survival</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Salvage Therapy - methods</topic><topic>solid tumors</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Rate</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rizzo, Alessandro</creatorcontrib><creatorcontrib>Mollica, Veronica</creatorcontrib><creatorcontrib>Ricci, Angela Dalia</creatorcontrib><creatorcontrib>Maggio, Ilaria</creatorcontrib><creatorcontrib>Massucci, Maria</creatorcontrib><creatorcontrib>Rojas Limpe, Fabiola Lorena</creatorcontrib><creatorcontrib>Fabio, Francesca Di</creatorcontrib><creatorcontrib>Ardizzoni, Andrea</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rizzo, Alessandro</au><au>Mollica, Veronica</au><au>Ricci, Angela Dalia</au><au>Maggio, Ilaria</au><au>Massucci, Maria</au><au>Rojas Limpe, Fabiola Lorena</au><au>Fabio, Francesca Di</au><au>Ardizzoni, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>16</volume><issue>2</issue><spage>4409</spage><epage>4418</epage><pages>4409-4418</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>We performed a systematic review and meta-analysis to investigate the efficacy and safety of third-line (TLT) and salvage treatment (ST) in advanced or metastatic gastric cancer.
Eligible studies included randomized clinical trials assessing TLT and ST versus placebo or best supportive care. Outcomes of interest included: overall survival, objective response rate and disease control rate in TLT; progression-free survival in ST; grade 3–4 adverse events in ST.
The use of TLT and ST was superior to placebo or best supportive care in terms of prolonging overall survival and progression-free survival. Hematological toxicities were more frequent in ST.
TLT and ST are considerable and tolerable treatment options for patients with advanced or metastatic gastric cancer. Given the substantial heterogeneities affecting the efficacy analyses, these results have to be interpreted cautiously.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31793342</pmid><doi>10.2217/fon-2019-0429</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5257-8678</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-01, Vol.16 (2), p.4409-4418 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2320887873 |
| source | MEDLINE; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use biological therapy Cancer therapies chemotherapy Clinical trials Clinical Trials, Phase III as Topic Gastric cancer Gastroenterology gastrointestinal/colorectal Humans Medical prognosis Meta-analysis Metastasis molecular oncology Neoplasm Metastasis Oncology Progression-Free Survival Randomized Controlled Trials as Topic Salvage Therapy - methods solid tumors Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Rate Systematic review |
| title | Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Third-%20and%20later-line%20treatment%20in%20advanced%20or%20metastatic%20gastric%20cancer:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Rizzo,%20Alessandro&rft.date=2020-01-01&rft.volume=16&rft.issue=2&rft.spage=4409&rft.epage=4418&rft.pages=4409-4418&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2019-0429&rft_dat=%3Cproquest_cross%3E2473389951%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473389951&rft_id=info:pmid/31793342&rfr_iscdi=true |